<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11011426</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Robles García, J E</dc:author>
<dc:author>Sánchez Zalabardo, D</dc:author>
<dc:author>Rosell Costa, D</dc:author>
<dc:author>Berián Polo, J M</dc:author>
<dc:author>Arocena García-Tapia, J</dc:author>
<dc:author>Zudaire Bergera, J J</dc:author>
<dc:author>López Ferrandis, J</dc:author>
<dc:author>Sanz Pérez, G</dc:author>
<dc:author>Díez Caballero, F</dc:author>
<dc:description xml:lang="en">OBJECTIVE To assess the influence of neo-adjuvant hormone therapy on the pathologic stage, margins and disease-free survival in patients with T1-T2 prostate cancer after radical prostatectomy. MATERIAL AND METHODS Forty-two non-randomised, T1-T2 patients who underwent complete neo-adjuvant blockade and radical prostatectomy between 1988-1998 were included in the study. This group is part of a larger cohort of 220 T1-T2 patients treated with radical surgery. The group is compared to: a) the remaining patients (178) (Group I) and b) a selected group (54 patients) of consistent characteristics relative to clinical variables (Group II). Mean follow-up: 35 months; median: 32 months. RESULTS Compared to Group I patients with neo-adjuvant therapy show worse Gleason (p: 0.01), worse clinical stage (p: 0.02), higher rate of patients with high clinical risk (p: 0.03), and higher PSA (though not statistically different). No differences were seen relative to pathological status or margins. Compared to Group II (54 patients) no differences are found in clinical or pathological variables. Groups are comparable in terms of progression-free survival. CONCLUSIONS Neo-adjuvant hormone therapy in high clinical risk, T1-T2 patients does not involve improvement in pathological stage, margins or progression-free survival.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Jun </dc:date>
<dc:title xml:lang="es">Carcinoma de próstata. Prostatectomía radical. Influencia del tratamiento hormonal neoadyuvante.</dc:title>
<dc:title xml:lang="en">[Prostatic carcinoma. Radical prostatectomy. Impact of neoadjuvant hormonal treatment].</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
